Dr. Manish A. Shah on BBI608 in the Treatment Paradigm for Gastrointestinal Cancers
Shah says as more treatments become available, oncologists need to consider the order in which they give treatments to patients with gastric and gastroesophageal junction cancer.
Manish A. Shah, MD, medical oncologist, Bartlett Associate Professor of GI Oncology, Weill Cornell Medical Center at NewYork-Presbyterian Hospital, discusses how BBI608 might fit into the treatment paradigm for gastric and gastroesophageal junction cancer. Shah says as more treatments become available, oncologists need to consider the order in which they give patients treatments. He adds that not all gastric cancers are the same, so identifying which cancers would be best treated by a PD-1 inhibitor and which would be best treated by a stem cell inhibitor is crucial.
Older Adults Should Discuss Cancer Care Goals With Providers
December 5th 2023Older patients with stage 4 cancer often prioritize quality of life over survival time, according to recent research findings presented at the 2023 American Society of Clinical Oncology Quality Care Symposium.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
Cost-of-Care Conversations in Cancer Treatment Fall Short, New Study Reveals
December 4th 2023New treatments can come with high price tags, and a population-based, retrospective study revealed that fewer than 25% of patients with cancer have a documented conversation about the financial aspects of their treatment.
Read More
